In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators, CGEN- 15001T and CGEN-15022. Under the terms of the agreement, Bayer and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Preclinical stage milestones for CGEN-15001T immune checkpoint have been achieved and this program was transferred to the full control of Bayer for further development and preclinical development is on track. CGEN-15022 is at an earlier stage and further characterization studies of its role in anti-cancer immune responses are ongoing.
“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups at Bayer HealthCare